B&K Corporation Limited (HKG:2396)

Hong Kong · Delayed Price · Currency is HKD

3.900

+0.020 (0.52%)

Jul 21, 2026, 3:57 PM HKT

Market Cap	458.86M
Revenue (ttm)	580.89K +100.0%
Net Income	-232.56M
EPS	-2.32
Shares Out	117.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,800
Open	3.800
Previous Close	3.880
Day's Range	3.750 - 3.900
52-Week Range	3.500 - 37.200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 18, 2026

About B&K Corporation

B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. The company primarily focuses on the discovery, development, and commercialization of therapies for wound healing, currently platelet-derived growth factor (“PDGF”) drugs. The company’s pipeline comprised two Core Products including Pro-101-1 for the treatment of deep second-degree thermal burns, which has completed the statistical data analysis for Phase IIb... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 100

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2396

Full Company Profile

Financial Performance

In 2025, B&K Corporation's revenue was 522,000, an increase of 100.00% compared to the previous year's 261,000. Losses were -208.98 million, -1.54% less than in 2024.

Financial numbers in CNY Financial Statements